Login to Your Account

Starving for a Therapy in Chronic Fatigue

Ampligen Patient Hunger Strike; Hemispherx Takes CRL Tailspin

By Randy Osborne
Staff Writer

Wednesday, February 6, 2013
Hemispherx Biopharma Inc.'s complete response letter from the FDA in the wake of a negative advisory panel review of Ampligen for chronic fatigue syndrome (CFS) left the company weighing its chances of success in appealing the decision, and left patients without options.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription